• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Driver Mutations in Lung Cancer-Mapping the Way Forward.

作者信息

Chandrasekharan Arun

机构信息

Aster Malabar Institute of Medical Sciences, Govindapuram, Kozhikode, Kerala, India.

出版信息

South Asian J Cancer. 2022 Dec 30;11(3):181-182. doi: 10.1055/s-0042-1758549. eCollection 2022 Jul.

DOI:10.1055/s-0042-1758549
PMID:36588608
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9803547/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b43/9803547/747096730b6b/10-1055-s-0042-1758549-iv11n3editorial-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b43/9803547/747096730b6b/10-1055-s-0042-1758549-iv11n3editorial-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b43/9803547/747096730b6b/10-1055-s-0042-1758549-iv11n3editorial-1.jpg

相似文献

1
Driver Mutations in Lung Cancer-Mapping the Way Forward.肺癌中的驱动基因突变——探寻前进之路
South Asian J Cancer. 2022 Dec 30;11(3):181-182. doi: 10.1055/s-0042-1758549. eCollection 2022 Jul.
2
Targeted therapy in lung cancer: Are we closing the gap in years of life lost?肺癌的靶向治疗：我们是否在弥补失去的生命年限？
Cancer Med. 2022 Sep;11(18):3417-3424. doi: 10.1002/cam4.4703. Epub 2022 Mar 22.
3
To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations.是或否：携带有各种驱动基因突变的非小细胞肺癌的免疫治疗困境。
J Cancer Res Clin Oncol. 2023 Sep;149(12):10027-10040. doi: 10.1007/s00432-023-04919-4. Epub 2023 Jun 1.
4
Transcriptomic heterogeneity of driver gene mutations reveals novel mutual exclusivity and improves exploration of functional associations.转录组异质性揭示了驱动基因突变的新的互斥性，并提高了对功能关联的探索。
Cancer Med. 2021 Jul;10(14):4977-4993. doi: 10.1002/cam4.4039. Epub 2021 Jun 2.
5
Exploratory analysis of introducing next-generation sequencing-based method to treatment-naive lung cancer patients.对初治肺癌患者引入基于下一代测序的方法的探索性分析。
J Thorac Dis. 2018 Oct;10(10):5904-5912. doi: 10.21037/jtd.2018.09.108.
6
Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions.驱动基因突变型晚期非小细胞肺癌的治疗：当前应用与未来方向
Front Med. 2023 Feb;17(1):18-42. doi: 10.1007/s11684-022-0976-4. Epub 2023 Feb 23.
7
Characterization of driver mutations in Chinese non-small cell lung cancer patients using a novel targeted sequencing panel.使用新型靶向测序平台对中国非小细胞肺癌患者的驱动基因突变进行特征分析。
J Thorac Dis. 2022 Dec;14(12):4669-4684. doi: 10.21037/jtd-22-909.
8
Synchronous Presence of , Driver Mutations Along With PD L1 Overexpression in a Resected Early Stage Non-Small Cell Lung Cancer: A Case Report and Review of Literature.在一例切除的早期非小细胞肺癌中同时存在驱动基因突变以及PD-L1过表达：病例报告及文献复习
World J Oncol. 2018 Apr;9(2):50-55. doi: 10.14740/wjon1090e. Epub 2018 May 1.
9
Genomic Profiling of Driver Gene Mutations in Chinese Patients With Non-Small Cell Lung Cancer.中国非小细胞肺癌患者驱动基因突变的基因组分析
Front Genet. 2019 Oct 18;10:1008. doi: 10.3389/fgene.2019.01008. eCollection 2019.
10
QuaDMutEx: quadratic driver mutation explorer.QuaDMutEx：二次驱动突变探索器。
BMC Bioinformatics. 2017 Oct 24;18(1):458. doi: 10.1186/s12859-017-1869-4.

本文引用的文献

1
Correlation of (D4D6) Immunohistochemistry with Fluorescence In Situ Hybridization Assay in a Contemporary Cohort of Pulmonary Adenocarcinomas.当代肺腺癌队列中（D4D6）免疫组织化学与荧光原位杂交检测的相关性
South Asian J Cancer. 2022 Jun 25;11(3):249-255. doi: 10.1055/s-0042-1750187. eCollection 2022 Jul.
2
Prognostic Impact of Baseline Liver Metastasis in ALK Fusion-Positive Metastatic Lung Cancer: A Retrospective Review.ALK融合阳性转移性肺癌中基线肝转移的预后影响：一项回顾性研究
South Asian J Cancer. 2022 Mar 22;11(3):243-248. doi: 10.1055/s-0042-1742596. eCollection 2022 Jul.
3
Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non-Small-Cell Lung Cancer Using a Decision Analytic Model.
使用决策分析模型比较下一代测序与单基因检测在检测转移性非小细胞肺癌基因组改变中的经济影响
JCO Precis Oncol. 2019 Dec;3:1-9. doi: 10.1200/PO.18.00356.
4
Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring.液体活检在肺癌中的应用：在诊断、预测和治疗监测中的意义。
Mol Cancer. 2022 Jan 20;21(1):25. doi: 10.1186/s12943-022-01505-z.
5
Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: A multicenter study from India.ALK 重排转移性非小细胞肺癌的真实世界治疗和结局经验：来自印度的一项多中心研究。
Curr Probl Cancer. 2020 Jun;44(3):100571. doi: 10.1016/j.currproblcancer.2020.100571. Epub 2020 Mar 17.
6
Incidence of -Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients.印度重排非小细胞肺癌的发病率及克唑替尼在肺腺癌患者中的疗效
Lung Cancer (Auckl). 2020 Feb 24;11:19-25. doi: 10.2147/LCTT.S244366. eCollection 2020.
7
Comparison of next-generation sequencing and immunohistochemistry analysis for targeted therapy-related genomic status in lung cancer patients.肺癌患者靶向治疗相关基因组状态的二代测序与免疫组化分析比较
J Thorac Dis. 2019 Dec;11(12):4992-5003. doi: 10.21037/jtd.2019.12.25.
8
ROS1 mutation non-small cell lung cancer-access to optimal treatment and outcomes.ROS1突变型非小细胞肺癌——获得最佳治疗及预后情况
Ecancermedicalscience. 2019 Jan 29;13:900. doi: 10.3332/ecancer.2019.900. eCollection 2019.
9
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
10
Understanding and targeting resistance mechanisms in NSCLC.了解和靶向非小细胞肺癌的耐药机制。
Nat Rev Cancer. 2017 Oct 25;17(11):637-658. doi: 10.1038/nrc.2017.84.